๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Evommune, Inc. (EVMN)
NYSE: EVMN ยท Real-Time Price ยท USD
7.04
-0.20 (-2.76%)
At close: Nov 20, 2026, 4:00 PM EST
7.03
-0.01 (-0.14%)
After-hours: Nov 20, 2026, 7:30 PM EST

Evommune Earnings Call Transcripts

Fiscal Year 2026

  • The pipeline spans EVO301 in atopic dermatitis and ulcerative colitis, an MRGPRX2 migraine inhibitor, and oral VAV1 and TLR7/8 programs, with multiple 2027โ€“28 catalysts. $290M cash is expected to fund operations through H2 2029.

  • The portfolio's next milestones include EVO301 phase II studies in atopic dermatitis and ulcerative colitis, plus 2027 clinical data for EVO646 and the newly licensed VAV1 degrader. EVO756 migraine data are targeted for Q3 2027.

  • Investor update

    EVO570โ€™s Hinova license and $30M private placement support phase I and progression into RA phase II, with runway expected into H2 2029. Phase I data are expected mid-2027; RA phase II is planned for H2 2027.

  • Revised summary: The company advances a diversified pipeline with two co-lead assets: an IL-18 biologic for atopic dermatitis (strong Phase IIa, moving to IIb) and an oral MRGPRX2 inhibitor in Phase IIb for migraine. Other programs include a TLR7/8 inhibitor and STAT6 degrader. Financially robust, it leverages AI and adapts to industry trends.

  • AGM 2026

    The meeting covered the election of two directors and ratification of the independent auditor, with both proposals approved. No shareholder questions were submitted, and voting results will be reported on Form 8-K within four business days.

  • Status update

    A new phase IIb trial will evaluate EVO756, an oral MRGPRX2 antagonist, for migraine prevention, aiming to address unmet needs beyond current CGRP therapies. The program leverages strong mechanistic rationale and seeks to disrupt neuroinflammatory cycles in migraine, with top-line data expected in 2027.

  • Study result

    EVO301 met its primary and secondary endpoints in a phase 2A trial for moderate to severe atopic dermatitis, showing rapid, durable, and statistically significant efficacy with a clean safety profile after just two doses. The drug demonstrated broad anti-inflammatory activity and is advancing to phase 2B with a subcutaneous formulation.

Fiscal Year 2025

  • Study Result

    EVO756 demonstrated robust efficacy and safety in a phase II trial for chronic inducible urticaria, with 30% of patients achieving complete response and 93% showing improvement in key measures at four weeks. Results support further development in CSU and atopic dermatitis.